Bioxodes SA

Based in Belgium, Bioxodes SA is a healthcare company focused on developing innovative therapeutic solutions for thromboinflammation, particularly in treating conditions like intracerebral hemorrhage and ischemic stroke. Bioxodes SA, founded in 2013 and headquartered in Marche-en-Famenne, Belgium, specializes in therapeutic innovations for thromboinflammatory conditions. In December 2025, Bioxodes SA raised EUR 5. 5 million in series A funding from new investor Newton Biocapital Partners.

The funding was part of a larger EUR 16. 8 million series A round. The company is led by CEO Marc Dechamps and was established by Nicolas Havelange, who has a history of founding other ventures. Bioxodes focuses on innovative therapeutic solutions targeting thromboinflammation, specifically addressing conditions such as intracerebral hemorrhage (ICH) and ischemic stroke.

The company's lead product, BIOX-101, is a clinical-stage therapeutic that employs a unique mechanism of action to inhibit neutrophil activation and the formation of neutrophil extracellular traps (NETs), as well as blocking coagulation factors XIa and XIIa. This dual action aims to mitigate thromboinflammatory responses without increasing the risk of bleeding. Bioxodes’ products are aimed primarily at healthcare providers and institutions involved in stroke management, particularly in North America and Europe, where there is a critical need for effective therapies for hemorrhagic strokes. Bioxodes operates within a research-driven revenue model that involves partnerships and clinical collaborations to develop and commercialize its therapeutic candidates.

Revenue generation is anticipated from licensing agreements with pharmaceutical firms and potential direct sales to healthcare entities following regulatory approvals. The company is advancing BIOX-101 through clinical trials, particularly a Phase 2b trial for ICH, which is expected to contribute significantly to its revenue stream upon successful commercialization. The company plans to use the funding from December 2025 to advance its preparations for the Phase 2b trial of BIOX-101, strengthen development efforts and expand operations.